Off-brand versions of Lilly weight loss drug must be pulled off market, could mean higher prices
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop selling off-brand versions of the weight-loss drugs. The FDA has issued warnings against the off-brand versions, citing safety concerns.
FDA receives reports almost daily from different food companies regarding potential allergens or foodborne illnesses.
The U.S. Food and Drug Administration (FDA) has announced a final rule updating the definition of the nutrient content claim “healthy.” To qualify ...
The US Food and Drug Administration wants to redefine the meaning of healthy food, issuing a new rule Thursday that changes ...
Merck will discontinue its drug for a bacterial infection that can lead to fatal diarrhea, the U.S. Food and Drug ...
The US FDA approved Eli Lilly's Zepbound as the first ever medication for obstructive sleep apnea for patients who also have ...
While eggs haven’t historically been considered a "health food," the U.S. Food and Drug Administration (FDA) now classifies ...
The U.S. Food and Drug Administration on Monday approved Hikma Pharmaceuticals' generic version of Novo Nordisk's diabetes ...
The U.S. Food and Drug Administration reissued a decision first made by the agency in October that a shortage of the diabetes ...
The US Food and Drug Administration approved a new indication for Eli Lilly’s formulation of tirzepatide to treat moderate to ...
AstraZeneca has voluntarily withdrawn its marketing authorisation application with the EU's medicines regulator for its ...
Attempts to restrict pharmaceutical advertisements have failed many times over the years, often on First Amendment grounds.
Thanks to new rules implemented by the U.S. Food and Drug Administration (FDA), shoppers at major retailers, including Costco ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback